MedTrace Logo

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

NCT00702884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-03-21

Study results available
· View outcomes & findings →

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory esophageal or gastroesophageal junction cancer.

Conditions

  • Esophageal Cancer

Interventions

DRUG

sunitinib malate

Sunitinib 37.5 mg daily for a 4 week cycle

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Tony Bekaii-Saab

    lead OTHER

Principal Investigators

  • Tanios Bekaii-Saab, MD · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2013-09-17
Completion
2013-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702884 on ClinicalTrials.gov